Examorelin (Hexarelin)

Research protocols typically use 200-300 mcg/day, divided into 100 mcg doses administered 2-3 times daily via subcutaneous injection. Cycles of 8-12 weeks followed by 4-6 week breaks are common to prevent receptor desensitization. Partial tolerance to GH-releasing effects develops with prolonged use (50-75% decrease over weeks to months). Note: Examorelin and Hexarelin are the same compound.

Binds to growth hormone secretagogue receptors (GHS-R1a) on somatotroph cells in the anterior pituitary gland, activating intracellular signaling cascades involving calcium mobilization and protein kinase C (PKC) activation to trigger GH synthesis and release.

Interacts with hypothalamic neurons to enhance natural GHRH signaling, creating a dual mechanism of GH stimulation (direct pituitary + hypothalamic).

Functionally antagonizes somatostatin, reducing its inhibitory tone on GH release and allowing larger GH pulses than GHRH alone.

Activates cardioprotective effects through the CD36 scavenger receptor, independent of GHS-R1a activation and GH release. Demonstrated to reduce infarct size in ischemia-reperfusion models.

Potent stimulation of pulsatile GH secretion from the anterior pituitary, with IGF-1 elevation up to 220% above baseline reported in studies.

Promotes increased lean muscle mass through elevated GH and IGF-1 signaling, supporting protein synthesis and nitrogen retention.

Accelerated fat metabolism via GH-mediated lipolysis pathways.

Direct cardioprotective effects through endothelial nitric oxide synthase activation and improved cardiac contractility. Reduced infarct size by 25-40% in animal models of ischemia-reperfusion injury.

Enhanced tendon and ligament strength, improved joint health, and faster recovery from injuries and training.

GH release patterns may improve deep sleep quality and overall energy levels.

Identification of alexamorelin consumption biomarkers using human hepatocyte incubations and high-resolution mass spectrometry.

Journal of analytical toxicology · Pobee E, Daziani G, Gameli PS

SARS-CoV-2 RNA Dependent RNA polymerase (RdRp) - A drug repurposing study.

Heliyon · Ahmad J, Ikram S, Ahmad F

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology · Bayés M, Rabasseda X, Prous JR